Irbesartan/Hydrocholorthiazide Teva (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing the hormone from causing blood‑vessel constriction and aldosterone release. This leads to vasodilation and reduced sodium‑water retention, lowering blood pressure.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Patients should follow the prescriber’s instructions exactly.

Safety in pregnancy and lactation has not been fully established. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request this product, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapies, the Irbesartan/Hydrochlorothiazide combo offers dual mechanisms—vascular relaxation and diuresis—in a single tablet, which can improve adherence and provide more consistent blood‑pressure reduction than using either agent alone.

Store the tablets at room temperature, below 25 °C, in the original packaging. Keep them away from moisture and direct sunlight to maintain stability and potency.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe dehydration, electrolyte imbalances (especially low potassium), acute kidney injury, marked hypotension, and rare cases of angioedema. Patients should report symptoms such as faintness, rapid weight loss, swelling of the face or throat, or decreased urine output promptly.

The combination should be avoided in patients with known hypersensitivity to either component, severe renal impairment, anuria, or in those who are pregnant unless the benefits outweigh the risks. Clinicians should also exercise caution in patients with electrolyte disorders or severe liver disease.